Fructose consumption has increased by one-third from 1978 to 2004 in the western diet.
Inflammation also appears to play a role in the regulation of fructose absorption. Rodriquez-Yoldi and colleagues showed that IL-1β, an inflammatory cytokine, inhibits the transport of fructose. 7 After a 24 h fast, rabbits were injected with saline, IL-1β, or an inhibitor or activator of a kinase prior to IL-1β. Fructose transport was assessed using jejunal rings and purified brush border membrane vesicles, and uptake in both was measured. In the presence of PKC inhibitor, the effect of IL-1β on fructose uptake in intestinal tissue was reversed. In the presence of a PI3K inhibitor and activator, however, fructose uptake was not affected by IL-1β. Finally, a proteasome inhibitor decreased the effect of IL-1β, although it had no independent effect on fructose absorption, suggesting a role of NF-κB. To prove that the effects were independent of neuronal and hormonal effects, Caco-2 cells were cultured in a medium containing IL-1β and pre-incubated in solutions with kinase inhibitors or activators, and then incubated in a buffer with fructose. Fructose absorption was then measured. In the presence of a PI3K activator or PKC inhibitor, the effect of IL-1β on fructose absorption was reversed. In the presence of an inhibitor of NF-κB nuclear translocation, there was no inhibitory effect of IL-1β on fructose absorption. In summary, the results suggest that IL-1β could regulate the activation of PKCα 73, PI3K 55 and NF-kB proteins, and could exert an inhibitory effect on fructose intestinal absorption by a modification of GLUT5 insertion to brush-border membrane and/or the functional transporter activity. This article suggests a novel mechanism for fructose malabsorption, whereby the absorption of fructose is not entirely dependent on the abundance of transporters, but also on the inflammatory milieu of the intestinal epithelium.
Fructose is an important factor in the development of several metabolic disorders and has been implicated as a cause of a number of common functional gastrointestinal symptoms. A better understanding of the mechanisms of fructose absorption and its regulation may provide a key to discovering a means of preventing or improving these conditions. As described above, GLUT-5 appears to be a principal apical transporter of fructose in the small intestine, and its expression is upregulated by increased fructose intake via transcriptional activation, in the presence of ketohexokinase. However, other factors also appear to be necessary in fructose absorption. One such factor appears to involve the inflammatory milieu in the intestinal epithelium. Further investigation is needed to elucidate the mechanisms involved in fructose absorption and handling in humans, and better understand whether fructose consumption is actually the source of symptoms in patients with functional gastrointestinal disorders.
